Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume

The aim of this study was to compare the impacts of terazosin and tamsulosin, on prostate activity, i.e., serum prostate-specific antigen, total prostate volume (TPV), and transition zone volume (TZV). A total of 90 patients who presented with lower urinary tract symptoms (LUTS) secondary to benign...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2008, 23(3), , pp.509-513
Main Authors: Paick, Jae-Seung, Cho, Min Chul, Song, Sang Hoon, Kim, Soo Woong, Ku, Ja Hyeon
Format: Article
Language:English
Subjects:
Adrenergic alpha-Antagonists - administration & dosage
Aged
Aged, 80 and over
Humans
Logistic Models
Male
Middle Aged
Original
Prazosin - administration & dosage
Prazosin - analogs & derivatives
Prostate - pathology
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - drug therapy
Prostatic Hyperplasia - pathology
Retrospective Studies
Sulfonamides - administration & dosage
Treatment Outcome
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to compare the impacts of terazosin and tamsulosin, on prostate activity, i.e., serum prostate-specific antigen, total prostate volume (TPV), and transition zone volume (TZV). A total of 90 patients who presented with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), ranging in age from 52 to 83 yr (median 65 yr), were included in the study. Patients were given 0.2 mg tamsulosin, 2 mg terazosin, or 4 mg terazosin once daily for an average of 14 months (range, 6-56 months). Subjective (International Prostate Symptom Scores, I-PSS) and objective (maximal flow rate and post-void residual) parameters were assessed both at baseline and at treatment cessation. Serum prostate-specific antigen (PSA) levels were found to be unaffected by treatment (1.2 and 1.3 ng/mL). In total patients, multivariate analysis showed that baseline TPV was the only independent predictor of treatment-related TPV reduction. Moreover, baseline TPV > or =30 g was found to be associated with a higher likelihood of TPV reduction (odds ratio [OR], 3.939; 95% confidence interval [CI], 1.506-10.304; p=0.005), and a baseline TZV of > or =10 g was associated with a 7.1-times greater chance of TZV reduction (OR, 7.100; 95% CI, 2.428-20.763; p
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2008.23.3.509